To elucidate the mechanism of production of an inflammatory exudate, gingival crevicular fluid (GCF), from periodontal pockets in periodontitis, we examined the vascular permeability enhancement (VPE) activity induced by an arginine-specific cysteine proteinase, Ar-gingipain-1 (RGP-1), produced by a major periopathogenic bacterium, Porphyromonas gingivalis. Intradermal injections into guinea pigs of RGP-1 (> 10' M), or human plasma incubated with RGP-1 (> 10-9 M), induced VPE in a dose-and activitydependent manner but with different time courses for the two routes of production. VPE activity induced by RGP-1 was augmented by kininase inhibitors, inhibited by a kallikrein inhibitor and unaffected by an antihistamine drug.
Introduction
The declining incidence of dental caries in the general population has resulted in periodontal disease assuming major impor-tance as a cause of tooth loss (1, 2) . Adult periodontitis is strongly associated with infection by Porphyromonas gingivalis (formerly Bacteroides gingivalis) (3) (4) (5) (6) (7) , which is further demonstrated by the finding that implantation of this bacterium initiates the progression of periodontitis (8) . Proteolytic enzymes, which are produced in large quantity by this bacteria, are considered as important pathogenic agents (9-1 1 ). From a biochemical viewpoint, enzymes have been identified which hydrolyze complement factor CS (12, 13) , releasing a CSa-like neutrophil chemotactic fragment (14, 15) , which is likely to be involved in leukocyte infiltration of the gingiva. In addition, collagenases released (16, 17) may contribute to the loss of periodontal attachment associated with progressive periodontal disease.
The increased production and flow of gingival crevicular fluid (GCF)' is an important change in gingival tissues during periodontal infection, correlating with clinical indices of gingival inflammation (18) (19) (20) (21) (22) (23) . Indeed, salivary protein and albumin concentrations of individuals with periodontitis, which are an indication of plasma leakage due to vascular permeability enhancement (VPE), are significantly increased compared to healthy subjects (24) . These findings suggest that production of GCF is dependent on VPE induced at periodontitis sites, but little is known about the source or generation of VPE factor(s) and, more specifically, whether proteinase(s) of P. gingivalis are involved in their generation. Histamine, bradykinin, thrombin, and fibrinogen derivatives are potent VPE factors, and the generation of these factors is associated with the presence of trypsin-like proteinases. Histamine is released from mast cells by C3a, which is produced by the cleavage of complement factor C3 (25) . Bradykinin (BK) is generated from high molecular weight kininogen (HMWK) either directly, or indirectly, through activation of Hageman factor (HF) and/or plasma prekallikrein (PK) (26, 27) , a process which is also used by some microbial proteinases to generate BK (28) (29) (30) . Thrombin (31) and fibrinogen derivatives (32) for 30 min on ice, including 1 s pauses every 2 s of sonication). Unbroken cells and large cell debris were removed by centrifugation at 13,000 g for 15 min, and the clear supernatant which contained bacterial membranes, in addition to soluble components, was retained. Enzyme activity assay. The amidolytic, trypsin-like activity of crude P. gingivalis cell extract and purified RGP-1 was determined using Bz-L-Arg-pNA. Samples were preincubated in 0.1 M Tris-HCl, 200 mM Gly-Gly, 5 mM CaCl2, 10 mM cysteine, pH 7.6, for 5 min at 370C, and then assayed for amidase activity, using 1 mM substrate. The formation of p-nitroaniline was monitored spectrophotometrically at 405 nm.
Production of rabbit anti-gingipain IgG. Antibodies against gingipain were raised by subcutaneous inoculation of rabbits with 50 ,ug of enzyme emulsified in Freund's complete adjuvant. Booster injections with the same dose of enzyme, emulsified in Freund's incomplete adjuvant, were given after 2 wk and then monthly. Rabbits were bled after 10 wk by cardiac puncture and IgG prepared from the sera using PEG precipitation, according to the method of Polson et al. (37) .
Inhibition 
Results
VPE by RGP-I injected into guinea pig skin. Direct intradermal injection of RGP-1 induced VPE at concentrations of 10-8 M and above in a dose-dependent manner, but RGP-1 inactivated with TLCK had no effect ( Fig. 1 ). As expected, BK also induced VPE in a dose-dependent manner. The activity induced by RGP-1 showed a steeper stimulation than that found with BK, which showed an almost linear generation of VPE with a logarithmic increase of concentration ( Fig. 1 ). Using 10-8 M RGP-1, VPE increased until 15 min after injection (19-fold) and then diminished slowly, while BK-induced activity decreased rapidly after injection, most of the activity being eliminated in 15 min (Fig. 2) . These results indicate that the delayed genera- tion of VPE activity by RGP-1, in relation to direct injections of BK, is associated with its enzymatic activity and suggests that a cascade reaction may be involved in its production. Characterization of VPE. To identify the mechanism by which RGP-1 induced VPE, the effect of a variety inhibitors was tested. VPE production was not inhibited by simultaneous injection of diphenhydramine, an anti-histamine drug, whereas in controls the VPE generated by histamine was completely blocked (Fig. 3) . The simultaneous injection of SQ 20,881, an inhibitor of angiotensin I converting enzyme (38) , which is a BK inactivator, stimulated the VPE induced by RGP-1 (Fig.  3) . In controls this compound also augmented the VPE induced by BK but did not affect the VPE mediated by histamine. The simultaneous injection of SBTI completely inhibited the VPE produced by RGP-1, at a concentration at which this proteinase inhibitor does not affect the proteinase activity of RGP-1 ( 3), while having no effect on the VPE produced by BK VPE by human plasma treated with RGP-J. To investigate whether RGP-1 caused the production of VPE in man, human plasma was incubated with RGP-1, followed by injection into guinea pig skin. Human plasma-induced VPE in a dose-dependent manner after incubation with RGP-1 at concentrations as low as 10-9 M (Fig. 4) . The VPE of human plasma incubated with RGP-1 decreased markedly in the presence of SBTI or in the absence of 1,10-phenanthroline (Fig. 4) (an inhibitor of kininases [40] ). The VPE of plasma incubated with RGP-1 (10-9 M) increased linearly with incubation time (Fig. 5), indicating that no plasma proteinase inhibitors were affecting its production. ThCK-inactivated RGP-1 did not generate VPE activity from plasma even after longer incubation periods (Fig.  5) . These results indicate that RGP-1 acts in the same way in human plasma, inducing VPE through plasma kallikreinmediated BK generation.
VPE by deficient plasmas treated with RGP-J. To further investigate the mechanism of VPE production in human plasma treated with RGP-1, we examined its action in plasmas deficient in HF, PK, or HMWK. The enzyme generated VPE activity in HF-deficient plasma in a dose-dependent manner, but the VPE was 30-40% less than that of normal plasma (Fig. 6 ). Plasma deficient in either PK or HMWK did not stimulate VPE after incubation with RGP-1 (Fig. 6) . However, RGP-1 induced VPE from HMWK-deficient plasma reconstituted to normal levels by addition of HMWK (41) ted with PK (41) (Fig. 7 ). These results demonstrate that RGP-1 induces VPE by generating BK via activation of prekallikrein but not directly from HMWK.
Release of BK from plasma by RGP-1. To confirm the release of BK by RGP-1 in human plasma, BK antigen in plasma treated with RGP-1 was quantified. Release of BK antigen in normal plasma, treated with RGP-1, increased in a dose-dependent manner (Table I) , as it did in HF-deficient plasma, but in this case the BK release was much less than that from normal plasma. The release .f BK antigen from PK or HMWK-deficient plasmas was lower than the detection limit (Table I) . Considering the dose-response of VPE generated by BK (Fig. 1) , the concentrations of BK released from RGP-1-treated plasma cor- related closely to the VPE of RGP-l-treated normal plasma or plasmas deficient in HF, PK, or HMWK (Fig. 6 ). VPE by a mixture of purified PK and HMWK treated with RGP-1. To confirm the mechanism of VPE by RGP-1, we examined the generation of VPE activity from HMWK or the mixture of PK and HMWK, after treatment with enzyme. RGP-1 did not induce VPE from HMWK alone but could be demonstrated in a mixture of PK and HMWK, which was also dependent on (-), TBS supplemented with 1 mM dithiothreitol and 100 jig/ml bovine serum albumin was added to plasma instead of RGP-1; *, the concentration in the reaction mixture; < 4 means lower than 4 ng, the detection limit.
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Imamura et al. or TBS for 5 min at 25°C. The reaction was stopped by adding 400 gl of stop solution and 100 ul of the solution was injected intradermally into a guinea pig, pretreated with Evans blue. The VPE activity was assayed as described in Fig. 1 . The concentrations of HMWK, PK *, or PK* * were 70 yg/ml, 0.3 pg/ml, and 1 ug/ml, respectively. the concentration of PK (Fig. 8) . The amounts of BK released in RGP-1 -treated normal plasma or the mixture were 6.3 and 4.7 ng, respectively, and in other samples were lower than the detection limit (< 4 ng). The result further demonstrated that RGP-1 caused VPE through PK activation and subsequent BK release. Effects ofRGP-J -specific IgG and proteinase inhibitors on the VPE activity of RGP-J. To determine whether RGP-1 was the major VPE factor of clinically isolated P. gingivalis, we examined the effects of anti-RGP-1-IgG and proteinase inhibitors on the VPE induced by RGP-1 or extracts of P. gingivalis strain OMGS 100. The RGP-l-specific IgG inhibited VPE mediated by either RGP-1 or the extract by 90 and 95%, respectively (Fig. 9 ), but neither were affected by nonspecific IgG. Leupeptin, which inactivates arginine-specific P. gingivalis proteinases (35) , completely inhibited VPE generated by RGP-1 and that of bacterial extracts by 90%. Z-FK-CK, which rapidly inhibits KGP-1 (Pike, R. N., unpublished observation), did not affect VPE triggered by RGP-1, but reduced VPE by 27% in extracts. TLCK, which inhibits both arginine-and lysine-specific P. gingivalis proteinases (35) , reduced VPE by RGP-1 completely and VPE induced by extracts to only 6%. These results indicate that RGP-I is the major VPE factor of clinically isolated P. gingivalis.
Discussion
In an effort to systematically characterize the effects of virulence factors from P. gingivalis on the human system, particularly in view of their relationship to periodontal disease, we have examined the effect of cysteine proteinases from this or- ganism on VPE (and thus GCF production). All of the data obtained clearly indicate that the arginine-specific proteinase, RGP-1, has significant VPE inducing activity, with its mechanism of production being carefully characterized.
Although the biological concentration of RGP-l in GCF or dento-gingival pockets is not yet known, RGP-1 produced BK at low concentrations in human plasma (Table I) and induced VPE at IO-9 M (Fig. 4) , indicating that the enzyme would be functional in this system even at trace amounts. The data obtained by using deficient plasmas and purified PK and HMWK, clearly indicate that the major target for RGP-I in the activation of the cascade to release bradykinin is prekallikrein. While the mechanism of activation of PK by RGP-1 is not known, the cleavage site of prekallikrein by activated HF (/3-HF) is at the Arg371-Ile372 bond (42) . Since RGP-l is strictly arginine specific (34) , it probably cleaves the same site as that by /3-HF. This specificity for PK may not be complete, however, since 30-40% less VPE was induced in HF-deficient plasma (Fig. 6) , implying that RGP-l may also activate HF. Kallikrein also activates HF to form ,6-HFa which converts prekallikrein to kallikrein (43) (44) (45) (46) (47) (48) . Accordingly, kallikrein generation by RGP-1 in normal plasma could be augmented by this mechanism, while its production by RGP-I in HF-deficient plasma would lack this additional pathway, thus explaining why VPE is reduced relative to normal plasma. In a similar manner, Pseudomonas aeruginosa elastase has been found to specifically activate human PK (49), with the generation of kallikrein from HF-deficient plasma also being much less than from normal plasma (50) . Moreover, the VPE of plasma incubated with a low concentration of RGP-l ( 10 -9 M) increased linearly in an incubation time-dependent manner (Fig. 5 ), which suggests that there are no proteinase inhibitors in human plasma controlling RGP-1, as noted previously (34) .
It is known that some bacterial and mite proteinases can generate BK through activation of HF and/or PK (28) (29) (30) (49) (50) (51) (52) (53) . Proteinases from Serratia marcescens, house dust mite Dermatophagoides farinae, and Pseudomonas aeruginosa generate BK through either a combination of the activation of HF and/or PK or direct cleavage of HMWK. However, these proteinases require relatively high enzyme concentrations and long incubation periods at 370C to activate the human proteins (30, 49, 50, 52, 53) , and the results have not been confirmed in vivo. In our studies, however, RGP-I generated BK from human plasma at a much lower concentration and in a shorter incubation time at 250C (Fig. 4) , indicating that it is probably the most potent BK releasing enzyme among the bacterial proteinases studied to date.
In order to generate BK, RGP-1 must be in contact with PK and HMWK. Most of the trypsin-like activity of P. gingivalis (54, 55) , including RGP-1, is localized in the extracellular membrane vesicles and cell membranes of invasive strains of the bacteria (Potempa, J., unpublished observation). Hence, RGP-1 should be in contact with PK and HMWK present in periodontal interstitial fluid or plasma leaked into periodontitis sites, thereby producing kallikrein and, ultimately, the liberation of BK from HMWK. This would result in a continual cycle of plasma leakage, since VPE induced by RGP-1 would result in the further recruitment of PK and HMWK around RGP-1 due to continued plasma leakage after VPE induction. This is the most likely explanation for the clinical observation that exudation of GCF is continuous, with an estimated 1 ml of GCF passing from the gingiva into the mouth each day (57) .
Most of the VPE activity of P. gingivalis extracts was abolished by RGP-1-specific IgG, which also inhibited the VPE induced by RGP-1 (Fig. 7) . Therefore, RGP-1 is probably the major VPE factor of P. gingivalis. This is supported by data indicating that extracts in vivo were almost completely devoid of VPE inducing activity in leupeptin or TLCK-treated samples, both of which inhibit the proteinase activity of RGP-1, while Z-FK-CK (Fig. 7) , which only partially reduces the enzymatic activity of RGP-1, also lowered VPE production. The cleavage sites to release BK from HMWK are at Lys326-Arg364, and Arg371-Ser372 (57). Since P. gingivalis contains both arginine and lysine-specific enzymes it is possible that these could be direct release of BK from HMWK by the concerted action of these two enzymes. We have recently isolated a lysine-specific proteinase (KGP-1) from P. gingivalis (35) , but it alone did not induce VPE in vivo unless high concentrations were used (Imamura et al., unpublished observation). The addition of small amounts of RGP-I to the KGP-1 preparation did allow the induction of VPE in plasma, however, including PK-deficient plasma, indicating a direct release of BK from HMWK. Since the lys-specific proteinase (KGP) from P. gingivalis is totally inhibited by Z-FK-CK (Pike, R. N., unpublished observation), the finding that the VPE induced by extracts, in vivo, was only partially inhibited by this compound (Fig. 7) , indicates that KGP is not a major VPE factor of P. gingivalis.
Scott et al. purified a lysine-specific cysteine proteinase from P. gingivalis, which was claimed to directly cleave human HMWK, releasing BK antigen, as judged by an in vitro immuno-assay (58) . The mechanism for BK release by a lysinespecific proteinase is somewhat puzzling and it is more likely that, as indicated in their results, the enzyme preparation was significantly contaminated by activity cleaving after arginine residues (probably by RGP-1). Thus, it is likely that the release of BK in these assays was due to cleavage by both enzymes at the positions shown above in HMWK. An arginine-specific proteinase isolated by Hinode et al. (59) did not generate BK directly from HMWK in vitro, consistent with our results; however, another proteinase has been claimed to cleave after both arginine and lysine bonds, generating BK from HMWK directly (60) . Thus, although it may be possible to directly release BK from HMWK, much higher concentrations of the enzymes are required which, together with inhibitor studies, suggests that this would not be a significant mechanism in vivo, in relation to the activation of PK by low concentrations of RGP-1 as elucidated here.
The immunization of animals with whole cells of P. gingivalis, or its components, has been shown to be protective against experimental infection with the bacteria (61) (62) (63) . Since the existence of P. gingivalis and other periopathogens in the dentogingival crevice depends heavily on the continuous supply of nutrients delivered to periodontitis sites by GCF, it can be speculated that inhibition of GCF production may affect bacterial growth and/or virulence. Because RGP-1 is the major VPE factor of P. gingivalis and the VPE activity was blocked by RGP-1-specific antibody (Fig. 7) , it can be envisaged that immunization with purified RGP-1 may protect against P. gingivalis infection, a hypothesis which is now under investigation in our laboratory using a mouse model.
